Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccines for bluetongue

P K Murray1, B T Eaton

  • 1CSIRO Australian Animal Health Laboratory, Geelong, Victoria.

Australian Veterinary Journal
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

The development of bluetongue virus (BTV) vaccines in Australia involves evaluating live attenuated, killed, and virus-like particle (VLP) options. Each BTV vaccine type presents unique advantages and risks, influencing outbreak preparedness strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic diversity of bluetongue viruses in Australasia.

Veterinaria italiana·2010
Same author

Characterisation and monitoring of neutralisation-resistant VP2 phenotypes in BTV-1 isolates from northern Australia collected over a twenty-year period.

Veterinaria italiana·2010
Same author

Developing new orbivirus diagnostic platforms.

Veterinaria italiana·2010
Same author

Regional overview of bluetongue viruses in South-East Asia: viruses, vectors and surveillance.

Veterinaria italiana·2010
Same author

Complete genome sequence of Nariva virus, a rodent paramyxovirus.

Archives of virology·2008
Same author

Bats, civets and the emergence of SARS.

Current topics in microbiology and immunology·2007
Same journal

Basal body temperature as a biomarker of reproductive state in ewes: A multi-method comparison.

Australian veterinary journal·2026
Same journal

Impact of climate on Australian, non-Vector-borne infectious animal diseases: A scoping review.

Australian veterinary journal·2026
Same journal

A 9-year retrospective mortality review of captive orange-bellied parrots (Neophema chrysogaster) in Australia.

Australian veterinary journal·2026
Same journal

Antimicrobial-resistant Staphylococcus aureus isolated from Australian wildlife admitted to a veterinary hospital.

Australian veterinary journal·2026
Same journal

Asymptomatic thrombocytopenia in Akitas: a prospective cross-sectional study of platelet characteristics in an Eastern Australian population.

Australian veterinary journal·2026
Same journal

Partial amputation regrowth of P4 distal digit in an eastern grey kangaroo (Macropus giganteus): a case report.

Australian veterinary journal·2026
See all related articles

Area of Science:

  • Veterinary Virology
  • Immunology
  • Epidemiology

Background:

  • Australia faces potential bluetongue virus (BTV) outbreaks with 8 identified serotypes.
  • There is ongoing debate regarding optimal vaccine strategies for bluetongue disease control.

Purpose of the Study:

  • To review and describe current bluetongue virus (BTV) vaccine options under consideration.
  • To inform decisions on bluetongue vaccine selection for outbreak preparedness in Australia.

Main Methods:

  • Review of vaccine types: live attenuated virus, killed virus, and virus-like particles (VLP).
  • Analysis of production methods, efficacy, safety, and potential risks associated with each vaccine type.

Main Results:

  • Live attenuated vaccines are cost-effective and require a single dose but pose risks of teratogenicity and reversion to virulence.

Related Experiment Videos

  • Killed virus vaccines are safe but more expensive and require multiple doses.
  • Virus-like particles (VLPs) show promise but face challenges in commercial-scale production.

    • Conclusions:

    • Multiple bluetongue virus (BTV) vaccine options exist, each with distinct benefits and drawbacks.
    • Complex decisions regarding vaccine choice require scientific, industry, and governmental consensus.
    • Further research is needed to fully assess the effectiveness and production costs of killed virus vaccines.